Agios Pharmaceuticals (AGIO) stock is back in focus after the company shared detailed 52 week data from its RISE UP Phase 3 trial of mitapivat in sickle cell disease at EHA 2026.

Agios Pharmaceuticals shares have recently picked up momentum, with a 7 day share price return of 10.25% and a 30 day share price return of 12.87%. However, the 1 year total shareholder return is still down 10.31%, showing short term enthusiasm against a mixed longer term record.

If this sickle cell update has you thinking about where else progress in medicine could show up in the market, it is worth taking a look at 40 healthcare AI stocks

With Agios Pharmaceuticals stock up over the past quarter but still carrying a mixed multi year return record, is the current valuation overlooking the company’s rare disease pipeline strengths, or is the market already pricing in future growth?

Most Popular Narrative: 22.1% Undervalued

Agios Pharmaceuticals closed at $31.84, while the most followed narrative assigns a fair value of $40.88. This sets up a clear valuation gap built on specific growth and margin assumptions.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market, driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which should lift revenue growth in coming years.

Read the complete narrative. Read the complete narrative.

Want to see what is sitting behind that thalassemia launch story and the sickle cell catalyst, plus how revenue, profitability and valuation are paired in one model? The tension between rapid top line expansion, ongoing losses and a premium future earnings multiple is at the heart of this fair value.

Result: Fair Value of $40.88 (UNDERVALUED)

However, there is still meaningful risk to that Agios Pharmaceuticals upside case if PYRUKYND stumbles on safety or uptake, or if high R&D and SG&A spending keeps losses elevated longer than analysts expect.

Another View on Agios Pharmaceuticals Valuation

The narrative fair value for Agios Pharmaceuticals points to upside, but the current P/S ratio of 28.7x paints a very different picture. It sits well above the US Biotechs industry at 10.5x and the peer average at 2.9x, while the fair ratio is 0x. That gap signals considerable valuation risk if sentiment around revenue potential cools.

For a closer look at what the current price implies and how those multiples stack up against the fair ratio the market could move toward, have a look at See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed sentiment around Agios Pharmaceuticals, with both risks and rewards in play, it is worth reviewing the full picture for yourself and considering how that balance aligns with your goals by looking at the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Agios Pharmaceuticals?

If you are serious about putting this Agios Pharmaceuticals research to work, do not stop at one stock, widen your watchlist with focused, data driven screeners.

• Spot potential turnaround candidates that still trade at low share prices by scanning the 23 elite penny stocks with strong financials and checking which businesses back up their stories with real fundamentals.
• Target quality companies trading below their estimated fair value by using the 44 high quality undervalued stocks and see which opportunities currently sit off most investors’ radar.
• Prioritise resilience and capital preservation with the 67 resilient stocks with low risk scores so you are not left wishing you had balanced growth ideas with sturdier holdings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.